Education
- Doctor of Medicine, Cleveland Clinic Lerner College of Medicine, 2026
- Master of Science in Biomedical Engineering, Case Western Reserve University, 2026
- Bachelor of Arts in Computer Science, University of California - Berkeley, 2021
- Bachelor of Arts in Biochemistry & Molecular Biology, University of California - Berkeley, 2021
Work and Research Experience
- Cancer Data Science Lab, NIH, Bethesda, MD
- 2024 - present
- Mentor: Eytan Ruppin, M.D., Ph.D.
- Software Engineer and Step 1 Tutor at HyGuru LLC
- 2024 - present
- Reference: Rahul Damania, M.D.
- Chung Lab, Cleveland Clinic Foundation
- 2021-present
- Mentors: Mina Chung, M.D. and John Barnard, Ph.D.
- Gladson Lab, Lerner Research Institute
- 2021-2024
- Mentor: Candece Gladson, M.D.
- Feng Lab, University of California, San Francisco
- 2018-2021
- Mentors: Jonathan Chou, M.D., Ph.D. and Felix Feng, M.D.
Projects
- Uworld2Anki
- Path2Space Web
- NBMErepeater
- Non-random Rotation Matching Algorithm (NRMA)
Publications
- Lodha R, Ouyang K, Carroll BT. Limitations of quantum artificial intelligence for enhanced skin cancer diagnosis: A scoping review. In preparation.
- Chang K, Delavan H, Yip E, Kasap C, Zhu J, Lodha R, et al. Modulating the PPARγ pathway upregulates NECTIN4 and enhances chimeric antigen receptor (CAR) T cell therapy in bladder cancer. Under review.
- Lodha R, Muller-Greven G, Maqbool MA, Guo L, Buchan G, Desai K, et al. Transcriptomic changes in glioblastoma predict a poor response to bevacizumab therapy: A novel therapeutic target for resistant tumors. Under review.
- Shen A, Arbesman M, Lodha R, Rayman P, Gastman B, Ko J, et al. Germline pathogenic variant (gPV) positive patients with melanoma exhibit improved response to checkpoint inhibitor immunotherapy. Journal of Investigative Dermatology. Accepted.
- Shen A, Arbesman M, Lodha R, Rayman P, Bungo B, Ni Y, et al. Clinical and Immunologic Features of Germline Pathogenic Variant–Positive Patients with Melanoma. Clinical Cancer Research. 2024;30(3):564–74. 10.1158/1078-0432.CCR-23-1964
- Shulman ED, Campagnolo EM, Lodha R, Cantore T, Hu T, Nasrallah M, Hoang DT, et al. Path2Space: An AI Approach for Cancer Biomarker Discovery Via Histopathology Inferred Spatial Transcriptomics. bioRxiv. 2024;2024-10. 10.1101/2024.10.16.618609
- Chou J, Robinson TM, Egusa EA, Lodha R, Zhang M, Badura M, et al. Synthetic Lethal Targeting of Cyclin Dependent Kinase-12-Deficient Prostate Cancer with PARP Inhibitors. Clin Cancer Res. 2024 Sep 25; 10.1158/1078-0432.ccr-23-3785
- Lodha R, Mehta N, Nielsen C. Non-random Rotation Matching Algorithm. medRxiv. 2023;2023–08. doi.org/10.1101/2023.08.28.23294718
- Shen A, Arbesman M, Lodha R, Rayman P, Gastman B, et al. Germline pathogenic variant-positive patients with melanoma exhibit improved response to checkpoint inhibitor immunotherapy. J Invest Dermatol. 2025;S0022-202X(25)00004-1.
Selected Presentations
- Lodha R, Shulman ED, Campagnolo EM, Cantore T, Hu T, Nasrallah M, Hoang DT, et al. Abstract B105: Predicting spatial transcriptomics from histopathology with Path2Space: AI charts breast cancer patients tumor immune microenvironment on an unprecedented scale. Cancer Immunology Research. 2025;13(2_Supplement):B105–B105.
- Chang K, Delavan HM, Zhu J, Kasap C, Yip E, Lodha R, et al. Abstract PR008: Modulating the PPARγ pathway to augment NECTIN4-targeting chimeric antigen receptor (CAR) T cell therapy. Clinical Cancer Research. 2024;30(10_Supplement):PR008–PR008.
- Shen A, Lodha R, Bungo B, Arbesman M, Pramod N, Ko J, et al. Germline variant positive melanoma patients exhibit an enhanced inflammatory microenvironment. Cancer Research. 2023;83(7_Supplement):5963–5963.
- Pramod N, Pavicic P, Lodha R, et al. Dissecting immuno-genomic pathways of response and resistance to immunotherapy in metastatic urothelial carcinoma in a real-world cohort. Cancer Research. 2023;83(7_Supplement):2278–2278.
- Pramod N, Dawsey S, Lodha R, et al. Characterizing immune-genomic signatures associated with response to immune checkpoint inhibitors (ICI) in patients with metastatic urothelial carcinoma (mUC). American Society of Clinical Oncology. 2023.
- Lodha R, Muller-Greven G, Guo L, Gladson C. Glioblastoma tumors that respond poorly to bevacizumab therapy show upregulation of an angiogenesis gene set. Cancer Research. 2023;83(7_Supplement):4593–4593.
- Asaeikheybari G, Osman MG, Lodha R, et al. PO-03-246 novel machine learning derived features of shape of pulmonary veins on CT scans are associated with risk of recurrence of atrial fibrillation post-ablation. Heart Rhythm. 2023;20(9):e153–e154.
Awards
- Honors in Molecular & Cell Biology, UC Berkeley, 2021
- Leadership Award, Cal Alumni Association, 2017-2021
- Full tuition scholarship, Cleveland Clinic Lerner College of Medicine, 2021-2026
- Medical Research Scholars Program, NIH Clinical Center, 2024-2025
Teaching Experience
- Course Facilitator - DeCal, University of California, Berkeley, Jan 2021 - May 2021
- Undergraduate Instructor - MCBC100A, University of California, Berkeley, May 2019 - Jan 2021
- Academic Intern - CS61A, University of California, Berkeley, May 2018 - Aug 2018
Skills
- Software: SLURM, Python, R, Java, C++, HTML/Javascript/CSS
- Languages: English (Native), Hindi (Native), Rajasthani (Native), Spanish (Fair)
- Hobbies: Tennis, Bouldering, Ceramics, Wood-working
Organizations and Leadership
- Co-president - Oncology Student Interest Group of CCLCM, 2021-2023
- Co-president - Medical Reallocation Initiative of CWRU SOM, 2021-2023
- Co-president - CaseMed Tech, 2022-2023
- Senior Advisor - Data Science Society, Jan 2021 - May 2021
- Directory of Academic Development - Data Science Society, May 2020 - Dec 2020
- President - Medical Reallocation Initiative, May 2020 - May 2021
- Chief Technology Officer - Medical Reallocation Initiative, May 2018 - May 2020